The map of China's cell and gene therapy (CGT) industry has just gained another key piece.

On March 26, 2026, Shenzhen Cell Valley Group, in partnership with the Shenyang state-owned platform, Shenyang Zhongdeka Life Technology Co., Ltd. ("Zhongdeka"), officially established the Shenyang Cell Valley Biopharmaceutical Co., Ltd. ("Shenyang Cell Valley"). With the completion of its business registration, this move marks the official implementation of Cell Valley's "National Public Service Platform Network Layout" strategy in the Northeast.

This collaboration is more than just a regional expansion; it is viewed within the industry as a landmark event, signaling the CGT sector's shift from "point-by-point breakthroughs" to a "systematic and platform-based" model.

A Strategic Move in the National Policy Window: Targeting the Core of Decree No. 818

With the imminent full implementation of the "Regulations on the Clinical Research and Clinical Translation Application of Biomedical New Technologies" (State Council Decree No. 818), the industry is entering an "accelerated clinical translation phase." Shenyang Cell Valley is clearly positioned as a "one-stop cell and gene therapy preparation and quality control public service platform for hospitals," focusing on serving:

Clinical research (IIT) in top-tier hospitals.

Cell therapy filing projects.

Clinical translation applications and implementation.

Real-world data (RWD) and future IND/registration application system support.

A New Paradigm of "Platform Company + State-Owned Synergy," Reconstructing the Industry's Underlying Logic

Unlike traditional CGT companies, Shenyang Cell Valley is not a single-product company but an infrastructure platform with capabilities in "production, quality control, clinical translation, and policy coordination." Its core innovations lie in three areas:

Platform Capability Output, Not Single-Point Technology Output

Leveraging Shenzhen Cell Valley's:

Industrial production capacity for viral vectors (RVV/LVV/AAV).

eVLP next-generation gene delivery system.

Cell preparation systems for stem cells, NK cells, γδT cells, iPSCs, CAR-T, TCR-T, and TILs.

A clinical collaboration network of over 100 top-tier hospitals.

This forms a "plug-and-play" regional preparation platform capability.

Deep State-Owned Participation, Solving the Industry's "Last Mile" Problem

Zhongdeka, as the Shenyang state-owned platform, provides:

Industrial carriers and policy resources.

Streamlined government approval and regional coordination.

Promotion of major municipal project implementation.

A Replicable "Shenyang Model" for Rapid National Rollout

Shenyang Cell Valley is the first "city-level cell and gene therapy public service platform benchmark project" with state-owned capital participation and professional team operations. This model can be rapidly replicated nationwide to form a national cell therapy infrastructure network.

Shenyang Cell Valley Represents a New Business Format: "Hospital-Driven + Platform-Based Services + Policy Compliance Closed Loop"

Through this powerful alliance, Shenyang Cell Valley will possess: clinical translation capabilities, production and quality control capabilities, policy understanding and implementation capabilities, and the ability to run multiple projects in parallel. This is why an increasing number of local governments are choosing to partner with Cell Valley.

The strategic value of establishing Shenyang Cell Valley lies in:

Filling the Void in the Northeast's CGT Industry

Currently, the Northeast region lacks a mature platform, and hospital clinical translation capabilities are fragmented. Shenyang Cell Valley will become the region's first systematic cell and gene therapy public service platform.

Driving a Hundred-Billion-Yuan Industrial Chain Extension

Centered on the platform's construction, it will drive the upstream (vectors, raw materials, equipment, talent development), midstream (cell preparation, testing), and downstream (clinical translation, radiation to Northeast Asian international healthcare) sectors, forming a complete industrial ecosystem.

Creating a "New Quality Productive Forces Model" for the Northeast's Revitalization

Against the backdrop of traditional industrial city transformation, cell and gene therapy is poised to become one of Shenyang's most dynamic strategic industries.

The establishment of Shenyang Cell Valley signifies that China's cell and gene therapy industry is moving from a "technology-driven" phase to a new era of "platform-driven, policy-driven, and industry-synergized" development.

 And Cell Valley is becoming the core driver of this new era.